Clinical trials: Pulmonary Hypertension, Primary
Pulmonary Arterial Hypertension
Mobile Health Intervention to Improve Exercise in Pediatric PH
Children and adults with pulmonary arterial hypertension (PAH) have severely reduced daily activity compared to healthy populations.
- Trial name
- MhOVE-PPH (NCT06549452)
- Testing
- mHealth Intervention, Usual Care
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Vanderbilt University Medical Center
Pulmonary Arterial Hypertension
Evaluation of Metformin Activity in Addition to Conventional Treatment of Grade II or III Pulmonary Arterial Hypertension (PAH)
Treatment of PAH includes exercise limitation, non specific agents (anticoagulants, diuretics and supplemental oxygen), pulmonary specific vasodilators and antiproliferative agents.
- Trial name
- MetHTAP (NCT01352026)
- Testing
- Metformin
- Where
- 2 sites in France
- Sponsor
- Nantes University Hospital
Pulmonary Arterial Hypertension
Study of ACT-293987 (NS-304) in Pulmonary Arterial Hypertension (PAH)
This is a multi-centre, multinational, open-label, single-dose acute hemodynamic study followed by randomized, double-blind, parallel-group, placebo controlled study.
- Trial name
- NCT00993408
- Testing
- ACT-293987 (NS-304)
- Where
- 8 sites in Austria, Belgium and 6 more
- Volunteers
- 43 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
Prevalence of the Hyperventilation Syndrome in Pulmonary Arterial Hypertension
Dyspnea is a major symptom in pulmonary arterial hypertension and people with the same haemodynamic have generally different degree of dyspnea in pulmonary arterial hypertension.
- Trial name
- HYPER2 (NCT03810443)
- Testing
- Hyperventilation test
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Idiopathic Pulmonary Arterial Hypertension
Beta-blockers in i-PAH
The main question of this study is: 'Is selective beta-blocker treatment safe and effective in reducing sympathetic overdrive, thereby improving RV function and remodeling in patients with iPAH?'.
- Trial name
- NCT01246037
- Testing
- Bisoprolol
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- Amsterdam UMC, location VUmc
Essential Hypertension
Physical Activity, Air Pollution, and High Blood Pressure
The investigators are investigating the effects of traffic-related air pollution (TRAP) on the cardiovascular and pulmonary response to exercise in patients with hypertension using a real world randomized, crossover study design.
- Trial name
- NCT05092672
- Testing
- Exercise
- Where
- Canada
- Volunteers
- 21 people
- Sponsor
- University of British Columbia
Pulmonary Arterial Hypertension, Cardiovascular Diseases
Telerehabilitation Program Via Videoconference PAH - Randomized Clinical Trial
Pulmonary arterial hypertension (PAH) is a serious, progressive disease that causes pulmonary arterial pressure, significantly affecting functional capacity and quality of life.
- Conditions
- Pulmonary Arterial Hypertension, Cardiovascular Diseases, Respiratory Disease Nursing, Hypertension, Pulmonary
- Trial name
- NCT05655481
- Testing
- Aerobic and Resistance training with rehabilitation, Health education
- Where
- Brazil
- Volunteers
- 50 people
- Sponsor
- University of Nove de Julho
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Xenon MRI Pulm Hypertension
The overall objective outlined in this study is to determine how pulmonary vascular remodeling in PAH at a cellular and pathological level is associated with changes in gas exchange physiology and hemodynamics (monitored with…
- Trial name
- Jupiter PH (NCT04991454)
- Testing
- 129Xe Hyperpolarized
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Bastiaan Driehuys
Pulmonary Arterial Hypertension
Revatio Special Investigation for Long-term Use in Pediatric Patients
Secondary data collection study: safety and effectiveness of Revatio in pediatric patients under Japanese medical practice
- Trial name
- NCT03364244
- Testing
- Sildenafil
- Where
- Japan
- Volunteers
- 1,023 people
- Sponsor
- Viatris Pharmaceuticals Japan Inc
Pulmonary Arterial Hypertension
Apabetalone for Pulmonary Arterial Hypertension
Throughout the past twenty years, numerous specific pharmacologic agents targeting the endothelial dysfunction associated with PAH have emerged.
- Trial name
- APPROACH-2 (NCT04915300)
- Testing
- Apabetalone
- Where
- Canada
- Volunteers
- 72 people
- Sponsor
- Laval University
Myeloproliferative Disorder, Myelodysplastic Syndromes
Early Recognition of Pulmonary Arterial Hypertension in Myelodysplastic and Myeloproliferative Diseases
Myelodysplastic and myeloproliferative Disease represent conditions with increased risk for pulmonary hypertension. However, the exact prevalence of pulmonary hypertension in these conditions is not known.
- Conditions
- Myeloproliferative Disorder, Myelodysplastic Syndromes, Pulmonary Hypertension
- Trial name
- NCT00909467
- Testing
- echocardiography, right heart catheterisation
- Where
- Austria
- Volunteers
- 86 people
- Sponsor
- Medical University of Graz
Pulmonary Arterial Hypertension
Epoprostenol for Injection in Patients With Pulmonary Arterial Hypertension
This is an open-label, nonrandomized extension to study AC-066A301. The study will assess safety and tolerability of ACT-385781A while providing a means for continuing treatment after ending participation in study AC-066A301.
- Trial name
- Epitome2ext (NCT01470144)
- Testing
- Epoprostenol
- Volunteers
- 41 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
Clinical Study to Assess the Long-term Safety, Tolerability, and Efficacy of Macitentan in Subjects With Eisenmenger Syndrome
Long-term study to evaluate if macitentan is safe, tolerable and efficient enough to be used for treatment of Eisenmenger syndrome.
- Trial name
- MAESTRO-OL (NCT01739400)
- Testing
- Macitentan 10 mg tablet, once daily.
- Where
- 51 sites in United States, Austria and 17 more
- Volunteers
- 217 people
- Sponsor
- Actelion
Vascular Disease
Efficacy Study of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension (PAH)
This open label, single-arm, non-controlled, multicentre study will determine the effect of ambrisentan on exercise capacity (6MWT) in Chinese subjects with PAH.
- Trial name
- NCT01808313
- Testing
- ambrisentan
- Where
- 12 sites in China
- Volunteers
- 134 people
- Sponsor
- GlaxoSmithKline
Interstitial Lung Disease, COPD
Pulmonary Hypertension SOLAR
The main goal of this study is to develop a noninvasive signature for pulmonary vascular remodeling in Group 3 PH patients, using hyperpolarized 129Xe magnetic resonance imaging (129Xe MRI).
- Conditions
- Interstitial Lung Disease, COPD, Pulmonary Arterial Hypertension
- Trial name
- PH SOLAR (NCT04778046)
- Testing
- Hyperpolarized 129Xe
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Bastiaan Driehuys
Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension
Hormonal, Metabolic, and Signaling Interactions in PAH
Our hypothesis is that optimal treatment of the dysfunctional metabolic pathways which underlie PAH will improve pulmonary vascular function and consequences of the disease.
- Conditions
- Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Scleroderma Associated Pulmonary Arterial Hypertension, Appetite Suppressant Associate PAH
- Trial name
- NCT01884051
- Where
- United States
- Volunteers
- 1,899 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Pulmonary Arterial Hypertension
Cardiac Function and Exercise Capacity in Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension is characterized by a progressive increase in pulmonary vascular resistance inducing shortness of breath and exercise intolerance.
- Trial name
- FONCE-HTAP (NCT02579954)
- Testing
- Rehabilitation
- Where
- 10 sites in France
- Volunteers
- 49 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Hypertension;Pulmonary;Primary
Observational Study of Actigraphy in Pediatric Pulmonary Arterial Hypertension
This study plans to learn more about activity levels in children with pulmonary hypertension. Pulmonary hypertension is a condition where the pressure in the lungs is higher than normal. This can affect the person's heart.
- Trial name
- NCT04745000
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Pulmonary Arterial Hypertension (PAH)
Long-Term Outcomes of Selexipag in Schistosomiasis-Associated Pulmonary Arterial Hypertension
Schistosomiasis-associated pulmonary arterial hypertension is a serious condition that can lead to shortness of breath, heart failure, frequent hospitalizations, and early death.
- Trial name
- PROPULSE-Sch (NCT07453030)
- Where
- Brazil
- Volunteers
- 30 people
- Sponsor
- Caio Júlio César dos Santos Fernandes
Pulmonary Arterial Hypertension
The Expression and Significance of MiRNA
It is not always known what causes PAH or what the best treatment is. The doctors doing this study would like to understand more about why some people develop PAH and other do not.
- Trial name
- NCT00806312
- Where
- United States
- Volunteers
- 207 people
- Sponsor
- Megan Ballinger